Ratings Smith & Nephew plc Berne S.E.

Equities

SN.

GB0009223206

Delayed Berne S.E. Other stock markets 09:05:19 2023-04-17 EDT			5-day change	1st Jan Change
- ^CHF	-.--%		-.--%	-100.00%

06-12	Smith & Nephew Launches Pre-Operative Planning, Modeling Services for Robotic-Assisted Surgical System	MT
06-10	European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading	MT

Strengths

The company's profit outlook over the next few years is a strong asset.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SMITH & NEPHEW PLC	-100.00%	11.19B		-
STRYKER CORPORATION	+15.68%	132B		A-
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-8.81%	8.08B		C
GLAUKOS CORPORATION	+42.76%	5.7B		B+
INSPIRE MEDICAL SYSTEMS, INC.	-17.67%	4.91B		C
AXONICS, INC.	+7.67%	3.42B		C-
ENOVIS CORPORATION	-19.40%	2.45B		B-
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-15.33%	2.02B	-	-
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-16.30%	1.89B		-
DOUBLE MEDICAL TECHNOLOGY INC.	-30.89%	1.61B		C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes